Aminopyridyl/pyrazinyl spiro[indoline-3,4′-piperidine]-2-ones as highly selective and efficacious c-met/ALK inhibitors

ACS Medicinal Chemistry Letters

Volumn 4, Issue 8, 2013, Pages 806-810

  Li, Jingrong ^a   Wu, Nan ^b   Tian, Yuanxin ^a   Zhang, Jiajie ^a   Wu, Shuguang ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

aminopyrazine; aminopyridine; anaplastic lymphoma kinase (ALK); cancer; Hepatocyte growth factor receptor (HGFR or c Met); inhibitor; small molecule; spiro indoline 3, 4 piperidine 2 one

Indexed keywords

6 [6 AMINO 5 [1,2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 3 PYRIDYL] 1' METHYLSPIRO [INDOLINE 3,4' PIPERIDINE] 2 ONE; AMINOPYRIDYL SPIRO[INDOLINE 3,4' PIPERIDINE] 2 ONE DERIVATIVE; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CRIZOTINIB; PIPERIDINE DERIVATIVE; PYRAZINYL SPIRO[INDOLINE 3,4' PIPERIDINE] 2 ONE DERIVATIVE; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER INHIBITION; CHEMICAL STRUCTURE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG EFFICACY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; HUMAN TISSUE; HYDROGEN BOND; IC 50; IN VITRO STUDY; IN VIVO STUDY; MITSUNOBU REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SINGLE DRUG DOSE; STOMACH CARCINOMA; SUZUKI REACTION; TUMOR XENOGRAFT;

EID: 84881392189     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml400203d     Document Type: Article

References (30)

1. Schmidt, L.; Duh, F.-M.; Chen, F.; Kishida, T.; Glenn, G.; Choyke, P.; Scherer, S. W.; Zhuang, Z.; Lubensky, I.; Dean, M.; Allikmets, R.; Chidambaram, A.; Bergerheim, U. R.; Feltis, J. T.; Casadevall, C.; Zamarron, A.; Bernues, M.; Richard, S.; Lips, C. J. M.; Walther, M. M.; Tsui, L.-C.; Geil, L.; Orcutt, M. L.; Stackhouse, T.; Lipan, J.; Slife, L.; Brauch, H.; Decker, J.; Niehans, G.; Hugson, M. D.; Moch, H.; Storkel, S.; Lerman, M. I.; Linehan, W. M.; Zbar, B. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas Nat. Genet. 1997, 16, 68-73
2. Ma, P. C.; Kijima, T.; Maulik, G.; Fox, E. A.; Sattler, M.; Griffin, J. D.; Johnson, B. E.; Salgia, R. c-MET mutational analysis in small cell lung cancer: Novel juxtamembrane domain mutations regulating cytoskeletal fucntions Cancer Res. 2003, 63, 6272-6281
3. Ma, P. C.; Jagadeesh, S.; Jagadeeswaran, R.; Fox, E. A.; Christensen, J.; Maulik, G.; Naoki, K.; Lader, A.; Richards, W.; Sugarbaker, D.; Meyerson, M.; Salgia, R. c-MET expression/activation, functions, and mutations in non-small cell lung cancer Proc. Am. Assoc. Cancer Res. 2004, 45, 1875
4. Di Renzo, M. F.; Olivero, M.; Martone, T.; Maffe, A.; Maggiora, P.; Stefani, A. D.; Valente, G.; Giordano, S.; Cortesina, G.; Comoglio, P. M. Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas Oncogene 2000, 19, 1547-1555
5. Lee, J. H.; Han, S. U.; Cho, H.; Jennings, B.; Gerrard, B.; Dean, M.; Schmidt, L.; Zbar, B.; Vande Woude, G. F. A novel germ line juxtamembrane Met mutation in human gastric cancer Oncogene 2000, 19, 4947-4953
6. Underiner, T. L.; Herbertz, T.; Miknyoczki, S. J. Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates Anti-Cancer Agents Med. Chem. 2010, 10, 7-27
7. Cui, J. J. Inhibitors targeting hepatocyte growth factor receptor and their potential therapeutic applications Expert Opin. Ther. Patents 2007, 17, 1035-1045
8. Cui, J. J.; McTigue, M.; Nambu, M.; Tran-Dubé, M.; Pairish, M.; Shen, H.; Jia, L.; Cheng, H.; Hoffman, J.; Le, P.; Jalaie, M.; Goetz, G. H.; Ryan, K.; Grodsky, N.; Deng, Y.-L.; Parker, M.; Timofeevski, S.; Murray, B. W.; Yamazaki, S.; Aguirre, S.; Li, Q.; Zou, H.; Christensen, J. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1 H -[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1 H -pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer J. Med. Chem. 2012, 55, 8091-8109
9. Furlan, A.; Colombo, F.; Kover, A.; Issaly, N.; Tintori, C.; Angeli, L.; Leroux, V.; Letard, S.; Amat, M.; Asses, Y.; Maigret, B.; Dubreuil, P.; Botta, M.; Dono, R.; Bosch, J.; Piccolo, O.; Passarella, D.; Maina, F. Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling Eur. J. Med. Chem. 2012, 47, 239-254
10. Colombo, F.; Tintori, C.; Furlan, A.; Borrelli, S.; Christodoulou, M. S.; Dono, R.; Maina, F.; Botta, M.; Amat, M.; Bosch, J.; Passarella, D. 'Click' synthesis of a triazole-based inhibitor of Met functions in cancer cells Bioorg. Med. Chem. Lett. 2012, 22, 4693-4696
11. U.S. FDA: News and Events. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm269856.htm (accessed May 17, 2013).
12. U.S. FDA: Drugs: Cabozantinib. http://www.fda.gov/Drugs/ InformationOnDrugs/ApprovedDrugs/ucm330213.htm (accessed May 17, 2013).
13. Palmer, R. H.; Vernersson, E.; Grabbe, C.; Hallberg, B. Anaplastic lymphoma kinase: signaling in development and disease Biochem. J. 2009, 420, 345-361
14. George, R. E.; Sanda, T.; Hanna, M.; Fröhling, S.; Luther, W., II; Zhang, J.; Ahn, Y.; Zhou, W.; London, W. B.; McGrady, P.; Xue, L.; Zozulya, S.; Gregor, V.; Webb, T. R.; Gray, N. S.; Gilliland, D. G.; Diller, L.; Greulich, H.; Morris, S. W.; Meyerson, M.; Look, A. T. Activating mutations in ALK provide a therapeutic target in neuroblastoma Nature 2008, 455, 975-978
15. Nakamura, H.; Tsuta, K.; Yoshida, A.; Shibata, T.; Wakai, S.; Asamura, H.; Furuta, K.; Tsuda, H. Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma. J. Clin. Pathol. 2013, in press
16. Schoppmann, S. F.; Streubel, B.; Birner, P. Amplification but not translocation of anaplastic lymphoma kinase in a frequent event in the oesophageal cancer Eur. J. Cancer 2013, 49, 1876-1881
17. Korashy, L.; El-Zawahry, H.; Abdou, S.; Shahin, D.; Sherif, F.; Farrag, W.; Abdel-Khalik, O.; Salem, H.; El-Sebaaie, A. Clinical significance of ALK-1 gene abnormalities in diffuse large cell lymphoma Clin. Med. Insights: Oncol. 2012, 6, 395-405
18. Casaluce, F.; Sgambato, A.; Maione, P.; Rossi, A.; Ferrara, C.; Napolitano, A.; Palazzolo, G.; Ciardiello, F.; Gridelli, C. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC Targeted Oncol. 2013, 8, 55-67
19. Wallace, G. C., IV; Dixon-Mah, Y. N.; Vandergrift, W. A., III; Ray, S. K.; Haar, C. P.; Mittendorf, A. M.; Patel, S. J.; Banik, N. L.; Giglio, P.; Das, A. Targeting oncogenic ALK and MET: a promising therapeutic strategy for glioblastoma. Metab. Brain Dis. 2013, in press
20. Fleuren, E. D. G.; Roeffen, M. H. S.; Leenders, W. P.; Flucke, U. E.; Vlenterie, M.; Schreuder, H. W.; Boerman, O. C.; van der Graaf, W. T. A.; Versleijen-Jonkers, Y. M. H. Expression and clinical relevance of MET and ALK in Ewing sarcomas Int. J. Cancer 2013, 133, 427-436
21. Lovly, C. M.; Heuckmann, J. M.; de Stanchina, E.; Chen, H.; Thomas, R. K.; Liang, C.; Pao, W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors Cancer Res. 2011, 71, 4920-4931
22. Ye, L.; Tian, Y.; Li, Z.; Jin, H.; Zhu, Z.; Wan, S.; Zhang, J.; Yu, P.; Zhang, J.; Wu, S. Design, synthesis and molecular docking studies of some novel spiro[indoline-3,4′]-2-ones as potent c-Met inhibitors Eur. J. Med. Chem. 2012, 50, 370-375
23. Ye, L.; Ou, X.; Tian, Y.; Yu, B.; Luo, Y.; Feng, B.; Lin, H.; Zhang, J.; Wu, S. Indazoles as potent c-Met inhibitors: Design, synthesis and molecular docking studies Eur. J. Med. Chem. 2013, 65, 112-118
24. Wu, S.; Zhang, J.; Wu, S.; Xu, W.; Wang, H.; Liu, Z.; Wan, S. Spiro Compounds, Method for Preparing the Same, and Application Thereof. CN101,851,237A, October 6, 2010.
25. de Koning, P. D.; McAndrew, D.; Moore, R.; Moses, I. B.; Boyles, D. C.; Kissick, K.; Stanchina, C. L.; Cuthbertson, T.; Kamatani, A.; Rahman, L.; Rodriguez, R.; Urbina, A.; Sandoval, A.; Rose, P. R. Fit-for-purpose development of the enabling route to crizotinib (PF-02341066) Org. Process Res. Dev. 2011, 15, 1018-1026
26. Jain, A. N. Surflex: Fully automatic flexible molecular docking using a molecular similarity-based search engine J. Med. Chem. 2003, 46, 499-511
27. Jain, A. N. Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search J. Comput. Aided Mol. Des. 2007, 21, 281-306
28. SM kinase assay panel. http://www.discoverx.com/services/drug-discovery-development-services/ kinase-profiling/kinomescan/scanedge (accessed May 20, 2013).
29. Fabian, M. A.; Biggs, W. H., III; Treiber, D. K.; Atteridge, C. E.; Azimioara, M. D.; Benedetti, M. G.; Carter, T. A.; Ciceri, P.; Edeen, P. T.; Floyd, M.; Ford, J. M.; Galcin, M.; Gerlach, J. L.; Grotzfeld, R. M.; Herrgard, S.; Insko, D. E.; Insko, M. A.; Lai, A. G.; Lélias, J.-M.; Mehta, S. A.; Milanov, Z. V.; Velasco, A. M.; Wodicka, L. M.; Patel, H. K.; Zarrinkar, P. P.; Lockhart, D. J. A small molecule-kinase interaction map for clinical kinase inhibitors Nat. Biotechnol. 2005, 23, 329-336
30. 50 profiling Assay Drug Dev. Technol. 2005, 3, 177-187